Sarah B. Noonberg - Apr 1, 2025 Form 4 Insider Report for Metagenomi, Inc. (MGX)

Role: Chief Medical Officer
Signature: /s/ Matthew L. Wein, attorney-in-fact
Stock symbol: MGX
Transactions as of: Apr 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/3/2025, 11:56 AM
Previous filing: Jun 20, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MGX	Common Stock	Award	$0	+14K	+13.95%	$0.00	114K	Apr 1, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MGX	Stock Option (Right to Buy)	Award	$0	+84K		$0.00	84K	Apr 1, 2025	Common Stock	84K	$1.32	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2	25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.